Developing precision nanoparticle-based drug delivery systems for Alzheimer's disease therapy

Alzheimer's disease (AD) is an irreversible neurodegenerative disease that has thus far suffered from unsatisfactory therapeutic outcomes. Despite ongoing research into AD pathogenesis and related drugs, few disease-modifying therapies are currently available. Moreover, efficient drug delivery is significantly hindered by low permeability of the blood-brain barrier (BBB) and non-specific distribution within the brain, further limiting the efficacy of existing anti-AD medications. Nanotechnology has recently emerged as a promising approach to overcome these challenges. This review aims to offer a comprehensive overview of recent advances in precision nanoparticle-based drug delivery systems for AD therapy. First, we outline the multiple pathological mechanisms and representative pathogenesis-inspired therapies of AD. Next, we summarize various types of nanoparticles that have been utilized in AD drug delivery, including polymeric, lipid-based, inorganic, and biomimetic nanocarriers. Subsequently, we highlight the nanoparticle-mediated strategies for cascaded precision drug delivery at different levels, focusing on both the BBB and specific pathologies or cell populations within AD lesions. Finally, we discuss potential challenges and prospects in employing precision delivery systems, aiming to accelerate the development and clinical translation of nanoparticle-based therapies for AD.

Abstract from PubMed Central (PMID 43022806, PMC13756178). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.